Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 AUD | -.--% | -.--% | -.--% |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 10.16M | C- | ||
-1.17% | 102B | B+ | ||
+2.87% | 96.09B | B+ | ||
+2.13% | 22.28B | B | ||
-14.77% | 21.4B | B+ | ||
-8.79% | 18.14B | A- | ||
-39.98% | 17.02B | A- | ||
-13.21% | 16.09B | B | ||
+8.55% | 13.83B | C+ | ||
+35.75% | 11.97B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BNOX Stock
- BNO Stock
- Ratings Bionomics